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                                                     1. INTRODUCTION 
 2 
Diabetes mellitus (DM) is a metabolic disease and a worldwide epidemic. Its hallmark 
is the presence of hyperglycemia. The characteristic pathologically elevated blood glucose can 
be caused by impaired insulin secretion, impaired action of insulin on the target tissue or both. 
The long-term consequences of this, at the beginning silent proceeding illness is damage that 
occurs to virtually every organ system particularly in the eyes, kidneys, blood vessels, nerves 
and heart. The principle of this disease is an autoimmune destruction of the beta cells of the 
pancreas which we call DM Type 1 (absolute insulin deficiency) or a rising insulin 
insensitivity of the body cells called DM Type 2 (relative insulin deficiency). The result is the 
same, an insufficient action of insulin. Constant hyperglycemia is the aftermath and leads to 
characteristic symptoms such as polyuria, polydipsia, weight loss, polyphagia, blurred vision, 
impaired growth and susceptibility to infections. Acute dramatic consequences like 
hyperglycemia with ketoacidosis or nonketotic hyperosmolar syndrome which can lead to 
death are also possible.  
Diabetic patients have to struggle with potential loss of vision; peripheral neuropathy with 
risk of foot ulcers, amputations, and Charcot joints; autonomic neuropathy causing 
gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction; 
increased incidence of atherosclerotic cardiovascular, peripheral arterial and cerebrovascular 
disease; hypertension and abnormalities of lipoprotein metabolism and finally nephropathy 
(today known as diabetic kidney disease (DKD)) leading to renal failure (1). 
 
 
1.1. Diabetic kidney disease 
 
1.1.1 Definition 
 
DKD is the chronic loss of kidney function and the major cause of End Stage Renal 
Disease (ESRD) in developed and developing countries (2). It is a progressive illness and is 
defined as diabetes with albuminuria (ratio of urine albumin to creatinine ≥ 30 mg/g) and 
impaired glomerular filtration rate (GFR) (<60 mL/min/1.73 m2) (3).   
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1.1.2. Etiology 
 
1.1.2.1. Pathogenesis and pathophysiology of diabetic kidney disease   
 
The pathogenesis of DKD is multifactorial and mainly based on pathologic metabolic 
(hyperglycemia) and hemodynamic (glomerular hypertension) changes in the kidney (4). 
  
The hemodynamic pathway reads as follows. Blood pressure in the glomeruli is under 
control of the efferent and afferent arterioles and their interplay of constriction or dilation. 
Hyperglycemia results in the accumulation of metabolic intermediate succinate which in turn 
acts on the vascular endothelium and triggers renin release from the juxtaglomerular 
apparatus by paracrine signaling (5). Activation of the renin angiotensin system (RAS) leads 
to production of angiotensin II and efferent arteriolar vasoconstriction which results in 
glomerular capillary hypertension and hyperfiltration. Similar to RAS is endothelin-1 (ET-1), 
which is also induced and is a potent vasoconstrictor and additionally plays a role in 
hypertension, endothelial dysfunction, inflammation and fibrosis (3). On top of that ET-1 
triggers mesangial cell hypertrophy, proliferation and extra cellular matrix (ECM) production 
(3).  
 
The metabolic pathway describes that a hyperglycemic environment blocks normal 
glycolysis. This results in an accumulation of glycolysis precursors which then upregulate 
four distinct pathways, the polyol pathway, hexosamine pathway, production of advanced 
glycation end products (AGEs), and activation of protein kinase C (PKC) (3). Additionally 
there is the so called inflammatory pathway because DKD is not entirely the result of 
hyperglycemia and changed hemodynamics (6).  The theory is, that there is a chronic low 
activation of the innate immune system mediated by NF- κB. NF- κB is a transcription factor 
that regulates genes for inflammation, immune response, apoptosis and several cytokines. 
Hyperglycemia, proteinuria and several other factors like viruses, bacteria, oxygen radicals 
and cytokines induce NF-κB release. NF- κB is essential in the interplay among the different 
factors leading to structural and functional alterations which are characteristic for DKD. 
Further there is a correlation between NF-κB and proteinuria and interstitial cell infiltration 
(6). There is also a greater production of inflammatory cytokines like TNF-α, IL 1, 6, 18 in 
diabetic patients. Other contributing factors are for example that podocytes in the presents of 
hyperglycemia have reduced autophagic activity and thus suffer additional damage (3). 
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1.1.2.2. Molecular basis of glomerular injury 
 
The polyol pathway describes the conversion of glucose to fructose. The side effects of 
this cascade is that there is a consumption of intracellular NADPH which is needed for 
regeneration of antioxidants (3). This will lead to additional cell stress and contribute to 
apoptosis. Additionally fructose is now known to be nephrotoxic and causes proteinuria and 
reduced GFR (3). The hexosamine pathway increases production of transcription factors like 
TNF-α and TGF-β1 (3). AGEs are created by irreversible glycation of proteins that occur in 
the presence of intracellular hyperglycemia. They damage the cells by modifying laminin, I 
and IV collagen and cause glomerular basement membrane (GBM) permeability (3). The 
alteration of collagen causes expansion of the ECM. Additionally AGEs can activate 
downstream signaling of IL 1, 6, TNF-α, TGF-β1, vascular endothelial growth factor (VEGF), 
platelet derived growth factor (PDGF), connective tissue growth factor (CTGF) and on top 
generate reactive oxidant species (ROS) (3). Hyperglycemia produces diacylglycerol (DAG) 
which is a cofactor for PKC activation hence it is constantly upregulated. PKC leads to 
prostaglandin E2 activation and nitric oxide release causing vasodilation of the afferent 
arterioles resulting also in glomerular hypertension (3).    
 
TGF-1 is the major fibrogenic growth factor responsible for of glomerulosclerosis, 
renal cell hypertrophy, increase of mesangial matrix components and interstitial fibrosis (3,7). 
It regulates differentiation, proliferation, apoptosis, adhesion and migration of various cell 
types. The main inducer of TGF-1 is PKC. It is mainly produced by mesangial, proximal 
tubular cells and infiltrating macrophages (7). TGF-1 induces in the glomerulus cellular 
hypertrophy, deposition of ECM biosynthesis in the form of collagen I, IV, V, VI, fibronectin 
and laminin (8). TGF-1 and IL6 promote the differentiation of naive T lymphocytes into 
proinflammatory T helper cells and they in turn cause inflammation and renal scarring. Those 
events block additionally ECM degradation and increase the vessel permeability and albumin 
leakage progress.   
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1.1.2.3. Other pathological changes present in the glomerulus 
 
 The renal corpuscle includes the glomerulus and the Bowman’s capsule and is the 
primary filtration unit of the kidney. The glomerulus is the beginning of the nephron and is 
composed of an afferent and an efferent arteriole, capillaries and mesangial cells who act as a 
scaffold. The blood passes through a filtration barrier. This barrier has three subunits. At first 
the blood has to pass through the pores in the capillaries, next through the GBM and finally 
through foot processes of the podocytes. Diabetic kidney disease can be divided in four types 
of glomerular lesions. Type one is GBM thickening, type two a is mild mesangial expansion, 
type two b severe mesangial expansion, type three nodular sclerosis and type four is global 
glomerulosclerosis of more than 50% (9). Glycosaminoglycans (GAG) which coats the 
podocytes play an important part of the negatively charged barrier of the glomerulus. 
Hyperglycemia affects GAG synthesis and thus also contributes to glomerular hyperfiltration 
and proteinuria (9). The podocytes are also an important part of the glomerulus and play a 
main role in blood filtration. In DKD there is a loss of podocytes, they detachment from the 
GBM and their processes are shortened (9). Finally mesangial expansion causes collapsing of 
the lumen of the capillaries and the weight of the kidney increases (9). 
 
 
1.1.2.4. Diabetic kidney disease as a tubulointerstitial disease 
 
The tubulointerstitial part of the kidney is composed of the tubular system, interstitial 
cells and vascular system. Progression of DKD leads to tubulointerstitial fibrosis and atrophy 
(9). It is now believed that the condition of the tubulointerstitium is in direct correlation to the 
state and progression of DKD especially in the advanced stages of DKD and that pathologic 
changes occur even before changes in the glomeruli are present (9).  
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1.1.2.5. Molecular basis of tubulointerstitial injury 
 
The tubulointerstitium is affected in similar fashion as the glomeruli. The main 
mediator is TGF- β1. It is induced by proteinuria and its components like AGEs, transferrin, 
albumin and fatty acids (10). It leads to tubular inflammation, fibrosis and oxidative stress. 
There is a complex pathophysiologic interaction between the proximal tubule, 
tubulointerstitium and diabetic milieu (9). The proximal tubule is the principal kidney unit of 
glucose reabsorption. To block the reabsorption of glucose in the proximal tubule could be 
one important step in the future prevention of DKD. Another important aspect of 
tubulointerstitial damage is chronic hypoxia mediated by angiotensin II, nitric oxide and ET1 
by impairing peritubular flow and decreased oxygen delivery to the tubules (9). Decreased 
erythropoietin production in the kidneys later on leads to anemia and intensifies tubular 
hypoxia (10).  
 
 
1.1.2.6. Pathological changes present in the tubulointerstitium  
 
The following changes can be observed in DKD. After chronic hyperglycemia the 
tubular basement membrane thickens at the same time as the GBM (11). Over time the tubules 
atrophy, interstitial fibrosis occur and late and severe manifestations are the detachment of the 
glomerulus from the proximal convoluted tubule (11).    
 
 
1.2 Apoptosis 
 
1.2.1. Definition 
 
 Apoptosis is the process of programmed cell death. It occurs constantly and is 
important during development and aging and overall maintains homeostasis and cell 
population (12). Apoptosis has to be differentiated from necrosis (oncosis). Necrosis is a toxic 
process where the cell is passive and follows an energy independent death (12). Usually many 
cells are affected. In contrast apoptosis is a controlled, active process and energy dependent 
(12). It can affect only one cell or few cells. Necrosis is characterized by cell swelling, 
karyolysis, pyknosis, karyorrhexis, disrupted cell membranes, release of cytoplasm and 
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usually inflammation (12). In comparison apoptosis has very different characteristics like cell 
shrinkage and convolution, pyknosis and karyorrhexis, intact cell membrane, cytoplasm is 
retained in apoptotic bodies and usually happens without inflammation because there is no 
release of chemotactic signals (12). The stimulus which inducts apoptosis can be the same 
which inducts necrosis only in a different intensity. Sometimes the apoptotic process can 
switch to necrotic process if the cell runs out of caspases or ATP (12).     
 
 
1.2.2. Molecular basis of Apoptosis 
 
 Apoptosis is mediated by several energy dependent steps. There are two main 
pathways. The extrinsic (death receptor) pathway and the intrinsic (mitochondrial) pathway 
(12). There is an additional pathway called granzyme B which is T cell mediated (12). All 
three pathways converge on the same execution pathway which starts with the cleavage of 
caspase 3 (12). The following events are DNA fragmentation; cytoskeletal and nuclear protein 
degradation; cross linking of proteins; formation of apoptotic body and finally phagocytosis 
(12). Caspases are the most important apoptotic enzymes. There are 10 caspases and they are 
divided into initiator, effector and inflammatory caspases (12). Their activation is irreversible 
and will lead to cell death. The extrinsic pathway is activated by a transmembrane receptor. 
They belong to the family of TNF receptors. Further downstream the receptor will induce 
death inducing signaling complex (disc) formation following caspase 8 activation and finally 
caspase 3 (12). The intrinsic pathway is the most interesting for us, since AIF is part of it.  
 
This pathway is without receptors and the stimuli act directly on mitochondria (12).  
Stimuli are for example lack of growth factors or hormones, radiation, toxins, hyperthermia or 
viral infection (12). These stimuli change the inner mitochondrial membrane and this in turn 
results in opening of the mitochondrial permeability transition pore (12). There is a loss of 
transmembrane potential and subsequent release of pro apoptotic proteins like cytochrome c 
which will from together with procaspase 9 an apoptosome (12). There is a second group of 
proteins released sometime later like endonuclease G and caspase activated DNase and finally 
AIF. Endonuclease G acts similar like AIF and is involved in DNA cleavage (12). The tumor 
suppressor gene p53 regulates Bcl-2 protein which in turn controls the mitochondrial 
membrane permeability and thus the apoptotic processes (12). This could be used in future for 
cancer research. All pathways lead to caspase 3 activation which will initiate the so called 
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execution pathway (12). Together with caspase 6 and 7 they are called execution caspases and 
act as intracellular cleavers which degrade plasma membrane, cytoskeletal and nuclear 
proteins (12).   
 
 
1.2.3. The dual role of AIF 
 
AIF is a flavin adenine dinucleotide (coenzyme, flavoprotein) containing, NADH 
dependent oxidoreductase residing in the mitochondrial intermembrane space whose specific 
enzymatic activity remains unknown (13). AIF has a dual task. At first scientists believed that 
it played only a role in caspase independent programmed cell death but today we know that it 
is also an important independent (from apoptotic function) factor for the cell survival in a 
manner of oxidative phosphorylation (OXPHOS) and thus for the generation of energy (14). 
Under normal circumstances AIF is located behind the outer mitochondrial membrane. If 
there is an apoptotic trigger AIF undergoes proteolysis and translocate to the cytosol and 
nucleus and causes chromatin condensation and large-scale DNA degradation. Cell death 
induced by AIF is through its proapoptotic activity once it is translocated to the nucleus not 
due to the loss of AIF from the mitochondria (15). AIFs role in apoptosis was discovered in 
1996 as it could maintain the apoptogenic ability in the presence of a pan caspase inhibitor 
(13). 
 
The cell surviving activity of AIF and its role in DKD is under current investigation. 
The ideal research outcome would be AIF as a tool to prevent DKD in diabetic patients. AIF 
has an important role to maintain mitochondrial and therefore kidney homeostasis. Deficiency 
in AIF results in defective OXPHOS by loss of complex I (part of the electron transport chain) 
activity (14). This deficiency alone was not enough to cause chronic kidney disease (CKD) 
but if diabetes was superimposed there were extensive changes in mitochondrial function 
which augmented the renal lesion (14). The conclusion is that AIF deficiency at least in the 
renal tubules is a risk factor for DKD (14).  
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2. OBJECTIVES 
 10 
AIM:  
The aim of our current study is to investigate the significance of AIF expression in the 
development of DKD by observing the expression of AIF in 2 weeks and 2 months’ diabetic 
kidney samples and then comparing them to healthy rat kidneys of the same age. 
 
HYPOTHESIS: 
AIF is deeply involved in programmed cell death. In diabetic kidney disease 
programmed cell death is a major event, so we expect AIF expression to be increased between 
2 weeks and 2 months in the diabetic rat kidney samples while in the control groups we 
presume no significant changes to be present. 
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3. MATERIALS AND METHODS 
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3.1. Ethical background 
  
The experimental protocol was allowed by The Ethics Committee of the University of 
Split, School of Medicine. All performed procedures were in accordance with the ethical 
standards of the institutional research committee and with the 1964 Helsinki declaration. 
 
 
3.2. Experimental Animals 
 
Male Sprague-Dawley rats were acquired from the University of Split, each of them 
weighing between 160 and 180 grams. The rats were raised under controlled conditions 
consisting of an environment temperature of 22±1°C and a 12-hour light/12-hour dark 
lighting schedule.  
 
 
3.3. Induction and validation of diabetes 
 
Experiments were performed using a type I diabetes rat model. Diabetes was 
introduced into the rats via an intraperitoneal injection of 55 mg/kg streptozotocin (STZ) 
dissolved in citrate buffer, at a pH of 4.5 after overnight fasting (16). Rats were given standard 
laboratory food, ad libitum, which is made up of 27% proteins, 9% fat and 64% carbohydrates 
(4RF21 GLP, Mucedola, Settimo Milanese, Italy).  
 
In order to verify diabetes within the rat models, the blood glucose and body weights 
of the rats were taken. Blood glucose level was measured in the morning at 8 am after 
overnight fasting. A One Touch Vita instrument (LifeScan, High Wycombe, UK) measured the 
plasma glucose of the rats by accessing tail vein blood, and a standard scale measured body 
weights. Rats with a glucose level above 16.5 mmol/L were considered diabetic and were 
used in subsequent experimentation. Success rate of diabetic induction was about 80%.  
 
 
The rats were separated into 2 groups based on the duration of diabetes as measured 
from the point of injection to the termination of the experiment (2 weeks, 2 months). Each 
experimental group was matched with a control group consisting of non-diabetic rats raised 
 13 
over the same time period. Control group rats were given intraperitoneal injections with just 
citrate buffer. 6 animals were raised for each of the 2 control groups and the 2 experimental 
groups, totaling 24 rat models. 
 
 
3.4. Tissue collection and immunohistochemistry 
 
Experimental rats were anesthetized with isoflurane (Forane, Abbott Laboratories, 
Queenborough, UK). Then, 300 mL of Zamboni’s fixative at pH 4 (4% paraformaldehyde and 
15% picric acid in 0.1 M phosphate-buffered saline) was perfused. Kidney samples were 
removed and post fixed in the same fixative solution for further analysis. 
 
The kidney samples were then processed with transverse cuts and then embedded in 
paraffin blocks. These blocks were then cut into 7 µm thick sections and investigated under 
immunofluorescence. After deparaffinization, tissue sections were rehydrated using alcohol 
and water. The samples were then thoroughly rinsed in distilled water and heated in a 
microwave oven with sodium citrate buffer (pH 6.0) at 95°C for 12 minutes. Samples were 
cooled at room temperature before being incubated with primary antibody. 
 
Following the application of the primary antibody, the tissue sample was kept 
overnight in a humidified chamber at room temperature. Sections were rinsed with PBS and 
incubated with the secondary antibody, donkey anti-goat from Abcam (ab150129, Cambridge, 
UK) for one hour in a humidified chamber. For nuclear staining 4',6-diamidino-2-
phenylindole (DAPI) was applied. Slides were mounted with the mounting media and 
coverslipped. Sections were observed and images were captured using a BX51 microscope 
(Olympus, Tokyo, Japan) equipped with a DP71digital camera (Olympus, Tokyo, Japan).  
 
Images were processed with CellA Imaging Software for Life Sciences Microscopy 
(Olympus Tokyo, Japan). Hematoxylin and eosin (HE) and Mallory staining were also 
performed. Kidney sections were analyzed focusing on two areas: cortex and medulla. For 
each of the listed areas, 5 non-overlapping fields were captured for analysis using 40× 
objective magnification, each field representing one image. Microphotographs were examined 
using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The percentage of 
the surface covered with positive cells (threshold area percent) were analyzed in six randomly 
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selected fields from each picture and compared between the groups. Quantitative analyses 
were performed for the following region of interests (glomeruli, proximal tubules, distal 
tubules and collecting ducts. In each region of interest percent of AIF positive cells was 
calculated and expressed as a mean±SD. 
 
Kidney sections were semi-quantitatively analyzed and described as four categories in 
regard to the staining intensity: (0) indicating the absence of any reactivity, (1) a mild 
reactivity, (2) moderate reactivity, (3) strong reactivity (Figure 8.). Two researchers 
independently analyzed the staining intensity. The amount of positive cells within each area 
(glomerulus, proximal convoluted tubule, distal convoluted tubule, collecting duct) were 
compared between the experimental diabetic groups and control groups. Distinct analyses 
were conducted for the 4 sections at each time point, and then the data was aggregated for all 
areas of the control and diabetic rats and evaluated.  
 
 
3.5. Statistics 
 
Mann-Whitney test was used for statistical analysis to examine the differences 
between the control groups and the diabetic groups. Data analysis was conducted using 
GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Data was expressed as a mean ± 
standard deviation, with p<0.05 serving as the marker of statistical significance. 
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4. RESULTS                                                                   
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HE staining reveals normal kidney morphology in 2 weeks’ control and 2 weeks’ 
diabetic groups and there are no obvious differences (Figure 1 and 2). However, there are 
characteristic morphologic differences between the 2 month control and 2 month diabetic 
groups. Those changes are mainly present in the glomeruli (Figure 1) and are related to 
glomerular hypertrophy and podocyte loss, which can lead to mesangial expansion and 
glomerular sclerosis. 
  
 
 
Fig. 1. Transversal section through the kidney tissue with the areas of interest: kidney cortex 
at 2 weeks in control (a) and diabetes (b); at 2 months in control (c) and diabetes (d). Scale 
bar 25µm. Legend: dt- distal tubule; g- glomerulus; pt- proximal tubule; ctrl- control; DM- 
diabetes mellitus type 1. 
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Fig. 2. Transversal section through the kidney tissue with the areas of interest: kidney medulla 
at 2 weeks in control (a) and diabetes (b); at 2 months in control (c) and diabetes (d). Scale 
bar 25µm. Legend: Cd- collecting ducts; ctrl- control; DM- diabetes mellitus type 1. 
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Mallory staining in the 2 weeks’ groups showed no obvious difference and normal 
kidney structures are present in both 2 weeks’ diabetic and 2 weeks control groups (Figure 3 
and 4 a, b). In the 2 months’ groups we can see changes in terms of extent of damage through 
replacement of podocytes with connective tissue cells (Figure 3 and 4 c, d). 
 
 
 
Fig. 3. Transversal section through the kidney tissue with the areas of interest: kidney cortex 
at 2 weeks in control (a) and diabetes (b); at 2 months in control (c) and diabetes (d). Scale 
bar 25µm. Legend: dt- distal tubule; g- glomerulus; pt- proximal tubule; ctrl- control; DM- 
diabetes mellitus type 1 
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Fig. 4. Transversal section through the kidney tissue with the areas of interest: kidney medulla 
at 2 weeks in control (a) and diabetes (b); at 2 months in control (c) and diabetes (d). Scale 
bar 15µm. Legend: Cd- collecting ducts; ctrl- control; DM- diabetes mellitus type 1. 
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AIF positive cells are displayed as red staining of cytoplasm within different areas of 
the cortex and medulla of kidneys during 2 weeks and 2 months after induction of diabetes 
mellitus (Figure 5 and 6). Cytoplasmic staining is better observed when images were merged 
with DAPI nuclear stain as shown on Figure 5 and 6. 
 
 
 
Fig. 5. AIF positive cells were seen as red staining of cytoplasm (arrows) within different 
areas of the cortex of kidneys. Co-localization of AIF and DAPI nuclear stain are displayed in 
the right column (merge). Kidney cortex in control and DM at 2 weeks (a, b) and 2 months (c, 
d). Scale bar 25µm. Legend: d- distal tubule; g- glomerulus; p- proximal tubule; ctrl- control; 
DM- diabetes mellitus type 1 
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Fig. 6. AIF positive cells were seen as red staining of cytoplasm (arrows) within different 
areas of the medulla of kidneys. Co-localization of AIF and DAPI nuclear stain are shown in 
the far-right column (merge). Kidney medulla in control and DM at 2 weeks (a, b) and 2 
months (c, d). Scale bar 25µm. Legend: cd- collecting duct; h- loop of Henle; ctrl- control; 
DM- diabetes mellitus type 1 
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Threshold area percent (TAP) of AIF positive cells in 2 weeks and 2 months of control 
and diabetic rat groups revealed statistically significant difference between control and 
diabetic group with higher threshold area percent of AIF in diabetic groups (Figure 7). 
 
 
 
Fig. 7. TAP of AIF positive cells in 2 weeks (2w) and 2 months (2m) of control and diabetic 
rat groups. Asterisk denotes significant difference: *p<0.05. Data presented as M±SD. 
Legend: ctrl- control; dm- diabetes mellitus type 1 
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AIF expression is located in the cortex (mainly present in the proximal and distal 
tubules but also in the glomeruli) and medulla (in the collecting ducts). Strong intensity of 
AIF expression can be seen in proximal and distal tubules in diabetic in both 2 weeks and 2 
months’ groups but also in 2-month control group in collecting ducts. AIF staining intensity 
was mild in both 2 weeks and 2-month control groups. In the control groups the glomeruli 
show no staining at all but they are moderately stained after 2 weeks and 2 months in the 
diabetic groups. There was no difference in AIF intensity between the control and diabetic 
groups in the collecting ducts (Figure 8.). 
 
 
 
Fig. 8. Staining intensity of AIF in glomeruli (g) proximal tubules (pt) distal tubules (dt) and 
in collecting ducts (Cd) in 2 weeks (2w) and 2 months (2m) of control and diabetic rat groups. 
Legend: ctrl- control; dm- diabetes mellitus type 1. 
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The percentage of AIF positive cells in the glomeruli is over all the lowest. Both 
control groups show low AIF expression (4% in 2 weeks ctrl; 7% in 2 month ctrl). In 
proportion the greatest rise in cell positivity is displayed from the 2 weeks control group to 2 
weeks diabetes group (38%) in glomeruli. The cell positivity of the 2 weeks diabetic group is 
cut nearly in half to 18% in the 2 month control group in glomeruli. A similar pattern even 
though not as drastic can be seen in the proximal convoluted tubular cells (92% positivity 2 
weeks DM; 89% positivity 2 month DM). The only decrease in AIF cell positivity from 2 
weeks control group (83%) to 2 month control group (80%) is seen in the proximal 
convoluted tubules. The distal convoluted tubules and collecting ducts show identical patterns 
in terms of a consistent rise of cell positivity from 2 weeks control to 2 month diabetic groups 
but not a great difference between the groups. The percentage of positive cells in the distal 
convoluted tubules are 24% in 2 weeks control; 36% in 2 weeks diabetic; 37% in 2 month 
control and 42% in 2 month diabetic of AIF cell positivity. The highest cell positivity is 
shown in the collecting ducts. Every group has more than 80% cell positivity.  
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Fig. 9. Percentage of AIF positive cells in glomeruli (g) proximal tubules (pt) distal tubules 
(dt) and in collecting ducts (Cd) of control and diabetic rat groups. Legend: 2w (2 weeks); 2m 
(2 months); ctrl- control; dm- diabetes mellitus type 1. 
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                                                                            5. DISCUSSION 
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In our experimental study we demonstrated with HE and Mallory staining that there 
are pathologic changes in diabetic rat kidney already 2 month after diabetes induction. There 
are additional contributing factors to renal sclerosis besides hypertension and hyperglycemia. 
According to Stadler et al. dyslipidemia is an important factor (17). At a baseline level renal 
epithelial cells use fatty acids as their energy source (17). The fact is, that DKD leads to 
abnormal fatty acid oxidation and therefore causes renal cell energy depletion and 
subsequently apoptosis, cell differentiation and sclerosis (17). Isermann et al. showed with 
their mice model that activated protein C (APC) is reduced in diabetic mice (18). APC 
modulates the mitochondrial apoptosis pathway and has thus an important role in maintaining 
normal kidney function by preventing glucose induced apoptosis in endothelial cell and 
podocytes which are part of the filtration barrier (18).  
 
The limitation of our study is that we did not gather data about kidney parameters like 
creatinine, albumin and blood level urea to further quantify DKD. Regarding AIF and its 
specific role in DKD, there are currently only a very limited number of studies available. 
Also, the sample size in the next studies could be increased. Further similar studies should try 
to find other factors responsible for apoptosis which have a stronger connection to diabetic 
kidney disease. The ultimate goal would be a factor which is the main mediator in apoptosis 
which in turn could be blocked by physicians and thus could terminate the 
development/progression of diabetic nephropathy.          
  
Regarding AIF we hypothecated that AIF and programmed cell death are strongly 
correlated. The ideal outcome of our experiment would have been that there are no significant 
changes in AIF expression in our 2 weeks control group in comparison to the 2 month control 
group. On top of that it would have been great if there would have been a strong rise in AIF in 
the diabetic groups compared to the control groups and that AIF would have been much more 
expressed in the 2 month diabetic group compared to the 2 weeks diabetic group. Such an 
ideal result is unfortunately not present. We achieve the closest result in the distal convoluted 
tubules and collecting ducts nevertheless the AIF cell positivity increased in the 2 month 
control groups.  
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We see a different view point in the staining intensity. The results of AIF intensity are 
closer to our hypothesis with a significant rise in staining intensity in the diabetic groups in 
comparison to the control groups even though there is still no difference between the diabetic 
groups. How to interpret those results is speculative. It is important to remember that AIF has 
a dual role, not only in apoptosis but also in cell function and homeostasis and that there are 
apparently differences in AIF expression in different parts of kidney like glomerulus, 
convoluted tubules, collecting ducts, cortex and medulla. Habib et al. found out that the renal 
tubules show pathologic changes earlier in comparison to the glomeruli and that the tubules 
could be overall more sensitive at the beginning of DKD (19). This could be true and 
underlined by the fact that in our study the highest amount of AIF cell positivity has been 
found in diabetic rats already after 2 weeks. If we would conduct the study again it would be 
interesting to see how the values would change over a longer period of time.  
 
 The results of our thesis underline the fact that there is a rise in AIF expression in 
DKD. This means that AIF is related to kidney sclerosis which is especially obvious in the 
glomeruli. The amount of positive cells rose from 4% to 38% in the 2 weeks groups and from 
7% to 18% in the 2 month groups. This is contradictory to what Coughlan et al. found out. In 
their study they concluded that AIF deficiency is a risk factor for diabetic kidney disease (14). 
Specifically, they stated that there are extensive changes in mitochondrial function if there is 
diabetes superimposed on AIF knockout mice (14). Furthermore, they found out that there is a 
fourfold decrease in renal cortical AIF in humans with DKD in comparison to healthy ones 
(14).  
 
 There is a lack of similar studies but the differences between our study and Coughlan 
et al. could by partially explained by the previously mentioned dual role of AIF. Already in 
2004 Jäättelä et al. pointed out that there are difficulties in measuring AIF correctly (20). 
They found out that AIF staining intensity in immunofluorescence increases remarkably upon 
translocation to the cytosol while a similar rise could not be demonstrated in immunoblot 
analysis (20). Consequently, it could be possible that we measured only the AIF present in the 
nucleus in other words the apoptotic AIF while Coughlan et al. measured the AIF present in 
the mitochondria and therefore the AIF responsible for cell survival. Further studies and 
methods should focus more on additional kidney parameter and it should be clear (if possible) 
which kind of AIF is examined.  
 
 29 
In conclusion, if we measure AIF we have to differentiate which kind of AIF we are 
currently measuring. When we are sure about it we can further assess the amount of AIF and 
only then it is possible to compare different studies. However, our study provides additional 
insight into AIF expression pattern during short term diabetes model and this knowledge 
might be important for the studies dealing with AIF as potential therapeutic target and marker 
of advancement of DKD. 
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6. CONCLUSION 
 31 
1. AIF is a major contributor in programmed cell death and therefore is an indicator 
for DKD. 
2. AIF expression in healthy kidneys is important to maintain oxidative 
phosphorylation and thus energy generation. 
3. Since AIF has two tasks it is important to differentiate them by all means.    
4. There are differences in expression of AIF in different cell populations of the 
kidney.  
5. In the future, it can be helpful in the diagnosis of DKD to focus on different areas 
of the kidneys besides the glomeruli.    
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7. SUMMARY 
 36 
 
Title: EXPRESSION PATTERN OF APOPTOSIS-INDUCING FACTOR IN THE 
KIDNEYS OF STREPTOZOTOCIN-INDUCED DIABETIC RATS 
 
Objectives: The aim of this study is to investigate the significance of AIF expression in the 
development of DKD by observing the expression of AIF in 2 weeks and 2 months diabetic 
kidney samples and then comparing them to healthy rat kidneys of the same age. 
 
Materials and methods: Diabetes mellitus (DM) was induced by i/p injecting 55 mg/kg 
streptozotocin (STZ) to male Sprague-Dawley rats, and was validated by measuring blood 
glucose level. Control group received citrate buffer. Animals were sacrificed after 2 weeks 
and 2 months. Cortex areas (glomeruli, proximal and distal tubules) and medullary areas 
(collecting ducts and distal tubules) were analyzed with antibodies raised against AIF. 
 
Results: AIF expression is located in the cortex as well as in the medulla of the kidney. In the 
cortex AIF is mainly present in the proximal convoluted tubules (pct) and in the medulla 
mainly present in the collecting ducts (cd). The highest percentage is present in the 2 weeks 
DM pct group with 92% positive staining. The cd shows a very mild incline in AIF positivity 
form 81% in the 2 weeks control group to 89% in the 2 month DM group. The staining 
intensity rose from moderate to strong staining. The pct showed a similar incline and the 
staining intensity increased stronger from mild to strong. The same rise in intensity was 
observed in the distal convoluted tubules but the relative increase in AIF positivity was 
stronger. What is striking is that the incline and absolute AIF staining intensity is roughly the 
same from the 2 weeks to 2 month in the control group and the DM group, that there is no big 
difference between the 2 weeks and 2 month DM groups. The absolute amount of AIF cell 
positivity is also roughly equal in the DM groups and in the DM 2 week group (38%) even 
twice as big as in the DM 2 month group (18%).  
Conclusions: Since AIF has a dual role, for the future it is important, if we want to compare 
studies to find a method to differentiate AIF in different states. If we manage this, AIF could 
become a parameter to assess kidney status in DKD and one day becomes a tool to block 
progression of DKD.   
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   9. CROATIAN SUMMARY 
 38 
NASLOV: IZRAŽAJ ČIMBENIKA INDUKCIJE APOPTOZE (AIF) U BUBREZIMA 
ŠTAKORA SA STREPTOZOTOCIN-INDUCIRANIM DIJABETESOM  
 
Ciljevi: Cilj ovog istraživanja bio je istražiti značaj AIF ekspresije u razvoju dijabetička 
bolest bubrega (DBB) promatranjem ekspresije AIF u 2 tjedna i 2 mjeseca bubrega bubrega, a 
zatim usporedbom sa zdravih bubrega štakora iste dobi. 
 
Materijali i metode: Diabetes mellitus (DM) je induciran i/p injektiranjem 55 mg/kg 
streptozotocina (STZ) mužjacima Sprague-Dawley štakora i validiran mjerenjem razine 
šećera u krvi. Kontrolne životinje su primale citratni pufer. Životinje su žrtvovane nakon 2 
tjedna i 2 mjeseca od indukcije dijabetesa ili citratnog pufera. Područja kore (glomeruli, 
proksimalni i distalni tubuli) i područja srži (sabirni kanali i distalni tubuli) analizirani su 
protutijelima na AIF. 
 
Rezultati: Izražaj AIF-a nalazi se u kori, kao i u  srži bubrega. U kori, AIF je uglavnom 
prisutan u proksimalnim zavojenim kanalićima (pct) dok je u srži uglavnom prisutan u 
sabirnim kanalićima (cd). Najveći postotak prisutan je u 2 tjednu DM pct skupine s 92% 
pozitivnih stanica. Cd pokazuje blago smanjenje pozitivnosti na AIF od 81% u kontrolnoj 
skupini od 2 tjedna do 89% u 2-mjesečnoj DM skupini. Intenzitet bojenja se povećavao od 
umjerenog do jakog bojenja. Slično smanjenje presutno je u pct, a intenzitet bojanja povećao 
se od blagog do jakog. Isti porast intenziteta zabilježen je u distalnim zavijenim kanalićima, 
ali relativno povećanje AIF pozitivnosti je bilo jače. Ono što je uočljivo je da je smanjenje i 
apsolutni intenzitet bojenja AIF-a otprilike isti od 2 tjedna do 2 mjeseca u kontrolnoj skupini i 
DM skupini, te da nema velike razlike između 2 tjedna i 2 mjeseca DM skupine. Apsolutna 
količina AIF pozitivnih stanica također je približno jednaka u skupinama DM i u dvjema 
skupinama od dva tjedna (38%), čak dvostruko veća u skupini DM od 2 mjeseca (18%). 
Zaključci: Budući da AIF ima dvostruku ulogu, za buduće studije je važno pronaći način 
razlikovanja AIF-a u različitim statusima, ako ih želimo usporediti. Ako se to može postići, 
AIF može postati parametar za procjenu stanja bubrega u DBB-a i eventualno ciljni alat za 
blokiranje napretka DBB-a. 
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